2020 Year in Review: Pharmacologic Treatments for COVID-19 by Saunders, Jessica L. & Davis, Michael D.
2020 Year in Review: COVID-19 Treatments
2020 Year in Review: Pharmacologic Treatments for COVID-19
Jessica L. Saunders, MD1 and Michael D. Davis, RRT, PhD, FAARC2*
1. Indiana University School of Medicine, Pediatric Pulmonology, Riley Hospital for
Children, Indianapolis, IN
2. Wells Center for Pediatric Research/Pulmonology, Allergy, and Sleep Medicine,
Riley Hospital for Children at Indiana University School of Medicine, Indianapolis,
IN. MDD1@IU.EDU
* indicates corresponding author.
Conflicts of Interest/Funding Disclosure: MDD is funded by NHLBI 1 PO1 HL128192 
and the Indiana CTSI UL 1 TR002529. He also is a patent holder of Optate and a co-
founder of Airbase Breathing Company. JLS is funded by the Cystic Fibrosis Foundation 
1st and 2nd Year Clinical Fellowship Grant.  
Page 1 of 21 Respiratory Care
_______________________________________________
This is the author's manuscript of the article published in final edited form as:
Saunders, J. L., & Davis, M. D. (2021). 2020 Year in Review: Pharmacologic Treatments for COVID-19. Respiratory 
Care. https://doi.org/10.4187/respcare.09153












Page 2 of 21Respiratory Care
2020 Year in Review: COVID-19 Treatments
3
Abstract
COVID-19, caused by SARS-CoV-2 infection, has led to a pandemic of acute 
respiratory illness. Pharmacologic treatments for COVID-19 have included treatments 
targeting infection prevention, prevention of viral replication, reducing inflammation and 
managing symptoms of respiratory failure caused by the disease. This is a review of key 
pharmacologic treatments for COVID-19 based on peer-reviewed articles from 2020.
Key Words: COVID-19, SARS-CoV-2, Remdesivir, REGN-CoV-2, Optate, Airway pH, 
Dexamethasone
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Introduction
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), was first identified in Wuhan, China at the end of 20191. Since that time, it has 
affected over 100 million people around the world leading to over 2 million deaths2. The 
virus causes an acute respiratory illness that the World Health Organization has termed 
Coronavirus Disease 2019 (COVID-19). Due to the severity and effects of this illness, 
great efforts have been undertaken to identify effective pharmacologic therapies to 
prevent infection, prevent viral replication, prevent damaging inflammation or to manage 
the symptoms of respiratory failure caused by the virus.
This reviews six pharmacologic treatments potentially useful for patients with 
COVID-19. Remdesivir, REGN-CoV-2, and Optate directly target viral infection and 
replication. Dexamethasone is a corticosteroid that reduces inflammation post-infection. 
Finally, oxygen and inhaled pulmonary vasodilators are used to treat and manage 
respiratory symptoms in patients with COVID-19.
The purpose of this article is to review the literature available in the past year 
regarding these pharmacologic therapies for COVID-19. Recent pharmacologic 
treatment strategies for COVID-19 will also be summarized. 
Methods
Pharmacologic agents included in the National Institute of Health (NIH) COVID-
19 Treatment Guidelines with the most supporting evidence at the time of this 
publication were included in this review3.  A PubMed search was conducted to identify 
articles published in 2020 that related to these COVID-19 pharmacologic treatments. 
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Searches were conducted using the key words “remdesivir”, “REGN-CoV-2”, “Optate”, 
“dexamethasone”, “oxygen” and “inhaled pulmonary vasodilators” in conjunction with 
“COVID-19”. A summary for each of the reviewed pharmacologic agents, based upon 
the findings of this literature search, is included below.
Discussion
Remdesivir
Remdesivir is an intravenous prodrug of an adenosine analog which incorporates 
into viral RNA and results in premature termination. It has a broad-spectrum antiviral 
activity against several viruses such as respiratory syncytial virus, Nipah virus, Ebola 
virus, Middle East respiratory syndrome, and severe acute respiratory syndrome 
coronavirus-1 (SARS-CoV-1)4-6. Remdesivir was authorized for emergency use by the 
FDA in May of 2020 for hospitalized adults with severe COVID-19. This emergency use 
authorization led to a double blind, randomized, placebo-controlled trial sponsored by 
the National Institutes of Health7. 
This initial trial enrolled hospitalized adults with confirmed cases of COVID-19 
and evidence of lower respiratory tract infections, treated them with either 10 days of 
remdesivir or placebo, and monitored their time to recovery. In this study, subjects who 
received remdesivir had a significantly decreased median recovery time compared to 
subjects who received the placebo (Figure 1, 95% CI, 9-11 vs 13-18). Subjects who 
received remdesivir were also more likely to have clinical improvement at day 15 (odds 
ratio, 1.5; 95% CI, 1.2-1.9, after adjustment for disease severity) when compared to 
those treated with placebo. Although there was no statistically significant difference in 
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mortality noted between the two groups, the authors concluded that remdesivir 
shortened the time to recovery and hastened clinical improvement when compared to 
the placebo group and may have prevented progression to more serious illness in some 
cases7.
A subsequent trial evaluated different courses of remdesivir (5 days vs 10 days) 
compared each other and the standard of care8. Subjects who received 5 days of 
remdesivir had significantly higher odds of having a better clinical status than those 
receiving standard care alone (odds ratio, 1.65; 95% CI, 1.09-2.48; P = 0.02). Of note, 
those who received 10 days of remdesivir therapy did not show a statistically significant 
difference when compared to the standard of care group (P = 0.18) and there was no 
significant difference in mortality between the three groups after 28 days. Although 
repeated studies suggest that remdesivir is a promising therapy for COVID-19, ongoing 
studies are needed to determine whether it reduces mortality8. 
REGN-CoV-2
REGN-CoV-2 is an antibody cocktail that prevents viral entry into human cells via 
the angiotensin converting enzyme 2 receptor. It is made up of two noncompeting, 
neutralizing human IgG1 antibodies, REGN10933 and REGN10987, that target the 
SARS-CoV-2 spike protein9. Viruses mutate frequently which may result in new mutant 
viruses that are not affected by a specific antibody – a process known as “viral escape”. 
By combining two (or more) antibodies, a therapy is less vulnerable to viral escape 
because the virus would have to mutate in multiple specific ways10. 
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Initial trials evaluated the effects of 8.0 g or 2.4 g of REGN-CoV-2 compared to 
placebo on non-hospitalized subjects with COVID-19. Subjects that received either dose 
of REGN-CoV-2 had a significantly decreased SARS-CoV-2 viral load than those that 
received the placebo (Figure 2, 95% CI, −1.02 to −0.11). Additionally, medical visits for 
COVID-19 were significantly decreased in subjects that received REGN-CoV-2 than 
those that received the placebo (95% CI, −29 to 11)11. As with remdesivir, further 
studies are needed to determine the effects of REGN-CoV-2 on mortality in patients 
with COVID-19.
Optate
Optate is an inhaled isotonic, isosmotic, alkaline medication designed to safely 
raise airway pH without irritating the airway epithelium. Raising intracellular pH partially 
prevents activation of SARS-CoV-2 in normal primary human airway epithelial (NHAE) 
cells, decreasing viral replication by altering endosomal trafficking and preventing viral 
entry and replication12. Optate has been previously shown to be safe to inhale in healthy 
human subjects and those with stable airways disease13. These studies also 
demonstrated that Optate raised airway lining fluid pH, with is airway epithelial 
extracellular pH. 
In 2020, in vitro studies demonstrated that Optate also safely increases 
intracellular pH of NHAE cells. Optate also ablated SARS-CoV-2 viral infection and 
replication in NHAE cells after 48 hours compared to placebo (Figure 3, P < 0.001). Due 
to its demonstrated safety profile in man and anti-viral effects in vitro, Optate inhalation 
may be well suited for a clinical trial in patients with COVID-19 infection14.
Page 7 of 21 Respiratory Care
2020 Year in Review: COVID-19 Treatments
8
Dexamethasone
Dexamethasone is a potent corticosteroid with anti-inflammatory properties that 
has often been used as a supplemental treatment for viral pneumonia15. Inflammation is 
a known component of COVID-19, leading to rationale of dexamethasone as a potential 
therapy16. The RECOVERY Trial Collaborative Group performed a randomized, 
controlled, open label trial comparing subjects treated with oral or intravenous 
dexamethasone (6 mg daily for up to 10 days) to those who received the standard of 
care alone and assessed mortality at 28 days. They found that those who received 
dexamethasone had significantly decreased mortality within 28 days compared to those 
who received the standard of care (Figure 4, 22.9% vs 25.7%, age-adjusted rate ratio, 
0.83; 95% CI, 0.75 to 0.93; P<0.001). Subjects requiring mechanical ventilation at the 
time of randomization also had lower mortality rates when receiving dexamethasone 
therapy compared to the standard of care (Figure 4, 29.3% vs. 41.4%; rate ratio, 0.64; 
95% CI, 0.51 to 0.81). Similarly, those receiving non-invasive oxygen therapy at the 
time of randomization had lower mortality rates when they were randomized to the 
dexamethasone group (Figure 4, 23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 
0.94). Of note, this decrease in mortality was not noted in subjects who did not require 
oxygen therapy at time of randomization (Figure 4, 17.8% vs. 14.0%; rate ratio, 1.19; 
95% CI, 0.92 to 1.55)17.
Oxygen
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Hypoxic respiratory failure is a severe complication of SARS-CoV-2 and affects 
approximately 19% of patients with COVID-1918. The Surviving Sepsis Campaign 
COVID-19 panel issued several recommendations regarding oxygen use in adults with 
COVID-19, including:
• Start supplemental oxygen if the peripheral oxygen saturation (SpO2) is < 92% (weak 
recommendation);
• Start supplemental oxygen if SpO2 is < 90% (strong recommendation);
• Maintain SpO2 no higher than 96% in patients with acute hypoxemic respiratory failure 
requiring oxygen (strong recommendation)19.
There is some rationale for heightened caution of the overuse of supplemental 
oxygen therapy in patients with COVID-19 due to concern for upregulation of SARS-
CoV-2 receptor expression in airway epithelium. Increased receptor expression could 
lead to increased susceptibility to SARS-CoV-2 infection. Myti et al compared levels of 
mRNA for genes encoding SARS-CoV-2 receptors in lung cells of mouse pups and 
preterm human infants exposed to chronically elevated FiO2 (>0.5)20. Levels of two 
different SARS-CoV-2 receptors, TMPRSS2 and TMPRSS11D, were both increased in 
the groups treated with high FiO2 (Figure 5, P < 0.001). Increased levels of SARS-CoV-
2 receptors could increase susceptibility to infection, however, further studies 
determining the effects of oxygen on SARS-CoV-2 infection in vivo are warranted20.
Inhaled Pulmonary Vasodilators
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Inhaled pulmonary vasodilators have been shown to improve oxygenation and 
VQ mismatch in patients with ARDS, which could lead to benefits in patients suffering 
from COVID-19. Inhaled pulmonary vasodilators include inhaled nitric oxide, 
prostacyclins and prostacyclin analogs. At the time of this publication, the Surviving 
Sepsis Campaign for COVID-19 panel does not recommends the routine use of inhaled 
pulmonary vasodilators for patients with COVID-19. They do recommend a trial of 
inhaled pulmonary vasodilators for mechanically ventilated adults with severe ARDS 
and hypoxemia secondary to COVID-19 and refractory to optimized ventilation and 
other rescue strategies. However, this is a weak recommendation with low quality 
evidence19. 
Franco et al. explored the mechanism of action of several inhaled pulmonary 
vasodilators and current ongoing clinical trials. They discussed the potential benefits of 
nitric oxide for benefit patients with COVID-19 by directly treating endothelial 
dysfunction/VQ mismatch, improving cardiac reserve, and by direct anti-viral effects21. 
Currently, a clinical trial is underway to assess these benefits as well as the safety of 
pulsed inhaled nitric oxide in patients with COVID-19 requiring supplemental oxygen22. 
Studies are also ongoing evaluating that effects of inhaled prostacyclin therapy on 
outcomes for mechanically ventilated adults with COVID-1923. 
Summary
In 2020, several pharmacologic agents have been identified and trialed for use in 
patients suffering from COVID-19. Several of these treatments target viral replication, 
inflammation, and symptom management. Due to the ongoing nature of this novel 
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pandemic, recommendations for treatment of patients with COVID-19 are ever evolving. 
The most up-to-date guidelines from the NIH can be found at 
https://www.covid19treatmentguidelines.nih.gov/. Knowledge of therapeutic options and 
best practice of their use is crucial for battling this pandemic. Of note, at the time of this 
publication, vaccination against SARS-CoV-2 is recommended as an effective 
prevention of COVID-1924.
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Figure 1: Remdesivir shortens time to recovery in patients with COVID-19. Subjects 
who received remdesivir had a median recovery time of 10 d (95% CI 9–11 d) 
compared to subjects who received the placebo whose median recovery time was 15 d 
(95% CI 13–18 d). Data from Reference 7.
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Figure 2: REGN-CoV-2 significantly decreases viral load compared to placebo. Time-
weighted average change in viral load from day 1 to day 7. Subjects that received 
REGN-CoV-2 SARS-CoV-2 had a significantly decreased SARS-CoV-2 viral load than 
those that received the placebo (95% CI −1.02 to −0.11). Data from Reference 11.
Figure 3: Optate decreases SARS-CoV-2 viral replication in Vero E6 and NHAE cells. 
A: PFUs were measured in culture media from control and Optate-treated Vero E6 cells 
infected with SARS-CoV-2. Optate ablated viral infection in the Vero E6 cells (P <.001). 
B: Control and Optate-treated primary NHAE cell cultures were infected with SARS-
CoV-2, PFUs in culture media were analyzed under similar conditions for 120 h, starting 
from 24 h after infection. After infection was established (24 h), viral infection was 
ablated in the Optate-treated cells (P <.001). From Reference 14.
Figure 4: Dexamethasone decreases mortality in hospitalized patients with COVID-19. 
Shown is the effect of dexamethasone on 28-d mortality according to respiratory 
support at time of randomization. Subgroups include all subjects, those undergoing 
mechanical ventilation, those receiving supplemental oxygen, and those who were 
receiving no oxygen at the time of randomization. Data from Reference 17.
Figure 5: Steady-state levels of lung mRNA transcripts encoding SARS-CoV-2 entry 
receptors and co-receptors in experimental animals and clinical subjects chronically 
exposed to elevated FiO2. A: mRNA levels of Ace2, Tmprss1, Tmprss2, 
and Tmprss11d in mouse pup lungs (5 animals per group) at post-natal day (P)2, 3, 5, 
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10, and 14, and then exposed to room air (FiO2 0.21; white bars) or hyperoxia 
(FiO2 0.85; black bars) for the first 14 d of post-natal life. B: mRNA levels were similarly 
determined for ACE2, TMPRSS1, TMPRSS2, and TMPRSS11D in the lungs of infants 
without (control, n = 8 subjects; white bars) or with bronchopulmonary dysplasia 
(BPD; n = 10 subjects; black bars). Data reflect mean ΔCt ± SD. Pairwise comparisons 
were made between the 21% O2 and 85% O2 groups by unpaired Student’s t test (A), 
and between the Ctrl and BPD groups by Mann-Whitney U test (B). *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001. From Reference 20, with permission.
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